Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background To compare the effects of oral capecitabine-containing chemotherapy regimens with i.v. 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in patients with gastrointestinal cancers.Methods A meta-analysis, based on individual patient data from six randomised non-inferiority trials, was carried out at the request of regulatory authorities to compare the effects of single-agent capecitabine or capecitabine-containing chemotherapy versus matched 5-FU-based regimens in terms of overall survival in patients with stage III colon, metastatic colorectal or advanced gastric cancer.Results Data from a total of 6171 patients with stage III colon cancer (n = 1987), metastatic colorectal cancer (n = 3868) or advanced gastric cancer (n = 316) were included. A total of 3097 patients were treated with capecitabine-containing chemotherapy and 3074 patients with 5-FU-containing chemotherapy. The unadjusted hazard ratio for overall survival for capecitabine-containing chemotherapy versus 5-FU-containing chemotherapy was 0.94 (95% confidence interval 0.89-1.00; P = 0.0489).Conclusions Oral capecitabine is at least equivalent to i.v. 5-FU in terms of overall survival in patients with gastrointestinal cancers. Capecitabine and 5-FU can be used interchangeably in these patient populations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Capecitabine, an oral FP that is enzymatically converted to 5-FU, was shown to be equivalent to 5-FU in survival benefit [138].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [138]
Citations
Cites
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Self-citationCapecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Self-citationCapecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Self-citationHoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Self-citationVan Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Self-citationCassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862
Self-citationKang, Y.-K., Kang, W.-K., Shin, D.-B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn717 · Cited by 764
Self-citationOkines, A. F. C., Norman, A. R., McCloud, P., Kang, Y.-K., & Cunningham, D. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp047 · Cited by 258
Self-citationSargent, D. J., Patiyil, S., Yothers, G., Haller, D. G., Gray, R., Benedetti, J., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4323 · Cited by 240
Tang, P. A., Bentzen, S. M., Chen, E. X., & Siu, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1935 · Cited by 236
Cited by
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Nie, K., Shi, L., Chen, Q., Hu, X., Jabbour, S. K., Yue, N., Niu, T., & Sun, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2997 · Cited by 414
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
Gao, Y., Xiao, X., Zhang, C., Yu, W., Guo, W., Zhang, Z., Li, Z., Feng, X., Hao, J., Zhang, K., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12380 · Cited by 189
Lee, A. W. M., Ngan, R. K. C., Tung, S. Y., Cheng, A. C. K., Kwong, D. L. �., Lu, T., Chan, A. T. �., Chan, L. L. K., Yiu, H. H. Y., Ng, W. T., et al. (2014) · Cancer · doi:10.1002/cncr.29208 · Cited by 178
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
Panczyk, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9775 · Cited by 122
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
Michel, M., Kaps, L., Maderer, A., Galle, P. R., & Moehler, M. (2021) · Cancers · doi:10.3390/cancers13102296 · Cited by 108
Shao, L., Liu, Z., Feng, L., Lou, X., Li, Z., Zhang, X.-Y., Wan, X., Zhou, X., Sun, K., Zhang, D.-F., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08659-4 · Cited by 92
“treatment optimization according to different pathological responses is essential to balance the benefits of nCRT versus its toxicity.(11) Therefore, it is important to establish a”
BackgroundRecent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Capecitabine, an oral FP that is enzymatically converted to 5-FU, was shown to be equivalent to 5-FU in survival benefit [138].”
BackgroundGastric Cancer: Clinical Aspects, Epidemiology and Molecular Background
Bornschein, J., Rokkas, T., Selgrad, M., & Malfertheiner, P. (2011) · Helicobacter · doi:10.1111/j.1523-5378.2011.00880.x · Cited by 67
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
Zhou, S., Peng, J., Xiao, L., Zhou, C., Fang, Y., Ou, Q., Qin, J., Liu, M., Pan, Z., & Hou, Z. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03734-4 · Cited by 66
Oral versus intravenous fluoropyrimidines for colorectal cancer
Chionh, F. J. M., Lau, D., Yeung, Y. H., Price, T. J., & Tebbutt, N. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008398.pub2 · Cited by 65
Micro RNA‐494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD
Chai, J., Dong, W., Xie, C., Wang, L., Han, D., Wang, S., Guo, H., & Zhang, Z. (2015) · IUBMB Life · doi:10.1002/iub.1361 · Cited by 64
Jorge, A. F., Aviñó, A. M., Pais, A. A. C. C., Eritja, R., & Fàbrega, C. (2018) · Nanoscale · doi:10.1039/c7nr08442k · Cited by 63
HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
Pous, A., Notario, L., Hierro, C., Layos, L., & Bugés, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411403 · Cited by 59
Gurusamy, K. S., Best, L. M., Tanguay, C., Lennan, E., Korva, M., & Bussières, J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012860.pub2 · Cited by 60
MacGregor, T. P., Maughan, T., & Sharma, R. A. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-200958 · Cited by 56
Mucinous ovarian cancer: A therapeutic review
Xu, W., Rush, J., Rickett, K., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.015 · Cited by 56
Iacovelli, R., Pietrantonio, F., Palazzo, A., Maggi, C., Ricchini, F., de Braud, F., & Bartolomeo, M. D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12449 · Cited by 55
Pariente, R., Bejarano, I., Rodríguez, A. B., Pariente, J. A., & Espino, J. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3154-2 · Cited by 55
PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer
Wang, H., Zhang, L., Xu, Y., Jin, Y., Pei, S., Zhang, D., Zhang, H., Zhou, B., Zhang, Y., & Lin, D. (2015) · Oncotarget · doi:10.18632/oncotarget.3775 · Cited by 51
Chemotherapy for Nasopharyngeal Carcinoma – Current Recommendation and Controversies
Sze, H. C., Blanchard, P., Ng, W. T., Pignon, J., & Lee, A. W. M. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.07.004 · Cited by 44
An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma
Ikoma, N., Raghav, K. P. S., & Chang, G. J. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.05.007 · Cited by 38
Sumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 36
Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
Petrelli, F., Zaniboni, A., Coinu, A., Cabiddu, M., Ghilardi, M., Sgroi, G., & Barni, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083022 · Cited by 36
Identification of novel germline polymorphisms governing capecitabine sensitivity
O’Donnell, P. H., Stark, A. L., Gamazon, E. R., Wheeler, H. E., McIlwee, B. E., Gorsic, L. K., Im, H. K., Huang, R. S., Cox, N. J., & Dolan, M. E. (2012) · Cancer · doi:10.1002/cncr.26737 · Cited by 35
Zhang, D.-Q., Guo, Q., Zhu, J., & Chen, W. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-16 · Cited by 35
Peixoto, R. D., Wan, D., Schellenberg, D. D., & Lim, H. J. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.04 · Cited by 32
Zou, X., Wang, Q.-W., & Zhang, J. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.009 · Cited by 30
Meulendijks, D., Henricks, L. M., Kuilenburg, A. B. P., Jacobs, B., Aliev, A., Rozeman, L., Meijer, J., Beijnen, J. H., de Graaf, H., Cats, A., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3137-0 · Cited by 29
Faugeras, L., Dili, A., Druez, A., Krug, B., Decoster, C., & D'Hondt, L. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.029 · Cited by 28
Latest developments and emerging treatment options in the management of stomach cancer
Delaunoit, T. (2011) · Cancer Management and Research · doi:10.2147/cmar.s12713 · Cited by 25
He, M.-M., Wu, W.-J., Wang, F., Wang, Z., Zhang, D.-S., Luo, H., Qiu, M., Wang, F., Ren, C., Zeng, Z.-L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082798 · Cited by 25
Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions
Fornaro, L., Vasile, E., Aprile, G., Goetze, T. O., Vivaldi, C., Falcone, A., & Al‐Batran, S. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.012 · Cited by 24
van den Broek, C. B. M., Bastiaannet, E., Dekker, J. W. T., Portielje, J. E. A., de Craen, A. J. M., Elferink, M. A. G., van de Velde, C. J. �., Liefers, G., & Kapiteijn, E. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.739730 · Cited by 24
Moore, J. L., Kumar, S., Santaolalla, A., Patel, P. H., Kapiris, M., Hemelrijck, M. V., Maisey, N. R., Hill, M. E., Lagergren, J., Gossage, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.021 · Cited by 23
Self-citationCytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells
Wiśniewska‐Jarosińska, M., Śliwiński, T., Kasznicki, J., Kaczmarczyk, D., Krupa, R., Bloch, K., Drzewoski, J., Chojnacki, J., Błasiak, J., & Morawiec-Sztandera, A. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0482-7 · Cited by 22
Roberto, M., Romiti, A., Botticelli, A., Mazzuca, F., Lionetto, L., Gentile, G., Paris, I., Falcone, R., Bassanelli, M., Pietro, F. R. D., et al. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2160-8 · Cited by 21
German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer
Lordick, F., Al‐Batran, S., Arnold, D., Borner, M., Bruns, C. J., Eisterer, W., Faber, G., Gockel, I., Köberle, D., Lorenzen, S., et al. (2023) · Gastric Cancer · doi:10.1007/s10120-023-01424-y · Cited by 19
Maharjan, A. S., McMillin, G. A., Patel, G. K., Awan, S., Taylor, W. R., Pai, S. G., Frankel, A. E., Nelson, C. L., Wang, B., Hosein, P. J., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.04.005 · Cited by 19
Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus
Cheng, A., Li, J., Vaid, A. K., Ma, B. B. Y., Teh, C. S. C., Ahn, J. B., Bello, M. D. G., Charoentum, C., Chen, L., Lopes, G. D. L., Jr., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.004 · Cited by 19
Wu, Z., & Deng, Y. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0597-y · Cited by 17
Geerts, J., van der Zijden, C. J., van der Sluis, P. C., Spaander, M. C. W., Nieuwenhuijzen, G. A. P., Rosman, C., van Laarhoven, H. W. M., Verhoeven, R. H. A., Wijnhoven, B. P. L., Lagarde, S. M., et al. (2024) · Cancers · doi:10.3390/cancers16071291 · Cited by 16
Wu, H., Chong-an, X., Chen, G., & Wang, J. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12444 · Cited by 16
Clua, A., Fàbrega, C., García-Chica, J., Grijalvo, S., & Eritja, R. (2021) · Molecules · doi:10.3390/molecules26061741 · Cited by 16
Zhong, L., Zhang, Y., Yang, J., Xiong, L.-F., Shen, T., Sa, Y., O'Yang, Y.-M., Zhao, S.-H., & Chen, J.-Y. (2015) · PubMed · Cited by 15
Ho, Y., Shih, C., Yeh, K.-T., Shi, B., Gong, Z., Lin, Y.-M., & Lu, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.061 · Cited by 14
Xu, L., Cheng, G., Lü, Y., & Wang, S. (2017) · Oncology Letters · doi:10.3892/ol.2017.5884 · Cited by 13
Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake
Aviñó, A. M., Clua, A., Bleda, M. J., Eritja, R., & Fàbrega, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115678 · Cited by 13
Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer
Wu, Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i21.3309 · Cited by 13
Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma
Tao, R., Li, Q., Gao, X., & Ma, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.8030 · Cited by 13
Capecitabine in the treatment of esophageal and gastric cancers
Popa, E., & Shah, M. A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.842974 · Cited by 13
Real-world resource use and costs of adjuvant treatment for stage III colon cancer
van Gils, C. W. M., de Groot, S., Tan, S. S., Redekop, K., Koopman, M., Punt, C. J. A., & Groot, C. A. U.-D. (2013) · European Journal of Cancer Care · doi:10.1111/ecc.12154 · Cited by 11
A Review of Capecitabine-Based Adjuvant Therapy for Gastric Cancer in the Chinese Population
Cheng, X., & Lu, Y. (2017) · Future Oncology · doi:10.2217/fon-2017-0558 · Cited by 11
[Oral chemotherapy: food-drug interactions].
Martínez, S. S., Rodríguez, J. A. M., & Carreño, E. R. (2015) · PubMed · doi:10.7399/fh.2015.39.4.8883 · Cited by 11
Clinical Management of Localized Colon Cancer with Capecitabine
Quidde, J., Arnold, D., & Stein, A. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8194 · Cited by 11
Sulaiman, S. H., Barzani, H. A. H., Omer, R. A., Jawhar, Z. H., & Mohammedsaeed, A. A. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70196 · Cited by 11
Li, H., Wang, L., Zhang, X., Xia, W., Zhou, X., Sui, H., & Fu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888075 · Cited by 10
Discovery of novel PARP1 inhibitors through computational drug design approaches
Shamim, M., Ali, M. S., Hossain, M. A., Hossain, M. A., Kavey, M. R. H., Hoque, M. M., Rahman, M. A., Harrath, A. H., & Rahman, M. H. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108366 · Cited by 10
Chachad, S., Purandare, S., Malhotra, G., & Naidu, R. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2007-7 · Cited by 9
Gurusamy, K. S., Best, L. M., Tanguay, C., Lennan, E., Korva, M., & Bussières, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012860 · Cited by 9
Cura, Y., Sánchez-Martín, A., Pete, N. M., González‐Flores, E., Martínez, F. M., Pérez-Ramírez, C., & Jiménez-Morales, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112548 · Cited by 8
Huang, Y., Wan, X.-W., Du, Y., Feng, Y., Yang, L.-S., Liu, Y., Chen, T., Zhu, Z., Xu, Y.-T., & Wang, C. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46050242 · Cited by 7
Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review
Troester, A. M., Parikh, R. R., Southwell, B. J., Ester, E. C., Sultan, S., Greeno, E. W., Arsoniadis, E. G., Church, T. R., Wilt, T. J., Butler, M., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae195 · Cited by 7
Retrospective analysis of patients with advanced or metastatic gastric cancer in Colombia
Novick, D., Leonardi, F., Pen, D. L. K., Restrepo, M. E. M., Avendaño, C., Siddi, S., Moneta, M. V., Haro, J. M., & Velásquez, J. C. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1617161 · Cited by 6
Khushman, M. M., Patel, G. K., Maharjan, A. S., McMillin, G. A., Nelson, C. L., Hosein, P. J., & Singh, A. P. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00210-2 · Cited by 6
Liu, X. F., Zhang, H., Sun, J., Yin, C., Liu, T. F., Yang, H., & Chen, L. H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2557-x · Cited by 4
Bergsland, E. K. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.09.002 · Cited by 4
Experimental and Theoretical Investigations of the Chemotherapeutic Drug Capecitabine
Chiş, M., Bonifacio, A., Sergo, V., Cainap, C. I., Chiş, V., & Baia, M. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131577 · Cited by 4
Bogaert, J. A., Cuyle, P.-J. A., & Cutsem, E. V. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_4 · Cited by 3
Fang, Y., Sheng, C., Ding, F., Zhao, W., Guan, G., & Liu, X. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2021.770767 · Cited by 3
Atención farmacéutica hospitalaria en pacientes en tratamiento con antineoplásicos orales
Vizcaíno, M. J. A. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 3
Systemic Therapy for Metastatic Colon Cancer: New Frontiers
Pumpalova, Y. S. (2024) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0044-1787826 · Cited by 2
Zhang, X., Dong, T., Li, X., Xu, C., Chen, F., Wang, S., & Wang, X. (2024) · Molecules · doi:10.3390/molecules29215077 · Cited by 2
Bogaert, J. A., Cuyle, P.-J. A., & Cutsem, E. V. (2012) · Springer eBooks · doi:10.1007/978-0-85729-787-7_4 · Cited by 2
Tian, J., Fan, X., Xu, R., Sun, Y., & Yang, G. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08700-6 · Cited by 2
Arora, R. (2013) · eScholarship (California Digital Library) · Cited by 1
Systemic chemotherapy for hepatic colorectal cancer
Kneuertz, P. J., & Kooby, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1454-8.00087-4 · Cited by 1
Cytolytic Epstein-Barr Virus Reactivation Therapy for EBV-Associated Gastric Carcinoma
Middeldorp, J. M., Novalić, Z., Verkuijlen, S. A. W. M., Greijer, A. E., & Middeldorp, J. M. (2020) · Clinical Oncology and Research · doi:10.31487/j.cor.2020.07.08 · Cited by 1
Popp, J. H., Weinberg, D. S., Enns, E. A., Nyman, J. A., Beck, J. R., & Kuntz, K. M. (2021) · Value in Health · doi:10.1016/j.jval.2021.07.017 · Cited by 1
Chemoresistance in Colorectal Malignancies: Molecular Mechanisms and Strategies to Overcome.
Verma, H. K., Ratre, Y. K., & Mazzone, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-72702-4_7 · Cited by 1
Pharmacogenetics of cytotoxic therapy in colorectal carcinoma
Erdeljić-Turk, V. (2015) · Hrčak Portal of scientific journals of Croatia (University Computing Centre) · Cited by 1
Is perioperative chemotherapy effective in patients with resectable gastric cancer?
Peña, J., Garrido, M., & Rada, G. (2014) · Medwave · doi:10.5867/medwave.2014.07.6008
Ålgars, A. (2012) · UTUPub (University of Turku)
Mutational analysis of KRAS and NRAS in metastatic colorectal cancer
Silva, R. O. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/2b6q-gd76
Precision Oncology: Present Status and Perspectives
Tagliaferri, P., Arbitrio, M., Ierardi, A., Ciliberto, D., Martino, M. T. D., & Tassone, P. (2017) · Current clinical pathology · doi:10.1007/978-3-319-55661-1_2
Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity
Li, R., Kim, D., Wheeler, H. E., DUDEK, S. M., Dolan, M. E., & Ritchie, M. D. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-018-0024-6
Corbí, M. P. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Wang, Y., Cheng, X., Zhao, H., & Gao, Q. (2019) · Transactions of Tianjin University · doi:10.1007/s12209-019-00213-y
Systemic chemotherapy for hepatic colorectal cancer
Fisher, S. B., & Kooby, D. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34062-5.00100-x
Locally Advanced Gastric Cancer Management: A Cost-Effectiveness Analysis
Prasath, V., Quinn, P. L., Arjani, S., Li, S., Oliver, J. B., Mahmoud, O., Jaloudi, M., Hajifathalian, K., & Chokshi, R. J. (2024) · The American Surgeon · doi:10.1177/00031348241227180
Sebio, A., & de Medicina, U. A. D. B. D. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
The effect of inflammatory cytokines on steroidogenesis in colon cancer cells
Banibakhsh, A. (2024) · University of Birmingham Institutional Research Archive (University of Birmingham)
Cura Cuevas, Y. A. (2024) · Institutional Repository of the University of Granada (University of Granada)
Correia, S. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Feng, Y., Tong, P., Fu, S., Lu, X., Zheng, L., Lai, J., & Lai, R. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.072563
García‐González, X. (2021) · e_Buah
Sharma, S., Kumar, K., Chauhan, G. S., Chauhan, S., Kriti, Kanwar, S. S., & Sharma, S. (2026) · Chemical Papers · doi:10.1007/s11696-026-04803-8
Sohaib, A., Hebesh, E. H., Elabd, N. S., Korani, O., Amin, M., Abd-Elhafiz, H. I., Badawy, A., & Hosny, S. (2026) · Współczesna Onkologia · doi:10.5114/wo.2026.162227
Chao, C.-Y., Tseng, K.-Y., Lin, H., & Shih, Y. (2026) · The Oncologist · doi:10.1093/oncolo/oyag424
Metadata
- Authors
- Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D.
- Affiliations
- University of Glasgow (GB)
- Memorial Sloan Kettering Cancer Center (US)
- University of Leeds (GB)
- Hospital Sírio-Libanês (BR)
- Asan Medical Center (KR)
- F. Hoffmann-La Roche AG (CH)
- Royal Marsden Hospital (GB)
- Corresponding author
- Cassidy, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 22
- Issue
- 12
- Pages
- 2604-2609
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2146874279
- Cited by
- 90
- References
- 17
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 3 · 2019: 3 · 2018: 8 · 2017: 11 · 2016: 6 · 2015: 6 · 2014: 9 · 2013: 8 · 2012: 8
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2913 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Roche
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- capecitabine, 5-fluorouracil, colorectal cancer, gastric cancer, metastatic colorectal cancer, stage III colon cancer, advanced gastric cancer, oral chemotherapy, overall survival, non-inferiority, individual patient data
- MeSH terms
- Capecitabine, Antineoplastic Agents, Deoxycytidine, Female, Fluorouracil, Humans, Male, Stomach Neoplasms, Colorectal Neoplasms, Multivariate Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.